Mojave Therapeutics, of Hawthorne, N.Y., named Jane Boswick vice president of corporate development, Christopher Fenimore director of finance, Joseph Mezzatesta director of quality and regulatory compliance and Michael Yamin director of intellectual property and licensing.
Nereus Pharmaceuticals Inc., of San Diego, appointed Kin Sing Lam director of microbiology and Antonio Caso vice president, corporate development.
Neurome Inc., of La Jolla, Calif., appointed Paul Greengard and Leslie Iversen to its scientific advisory board.
Oxigene Inc., of Waterown, Mass., added Dietmar Siemann to its scientific advisory board.
Pharmacopeia Inc., of Princeton, N.J., appointed Michael Lenahan executive vice president and general counsel and William DeLorbe executive vice president, human resources.
Structural Bioinformatics Inc., of San Diego, added David Muth as president and chief operating officer.
Syrrx Inc., of San Diego, appointed Carolyn Adler vice president of intellectual property and legal affairs.
Syrrx Inc., of San Diego, appointed William Ettouati chief business officer.
Transgene SA, of Strasbourg, France, appointed Michael Hubert vice president, business development.
Transkaryotic Therapies Inc., of Cambridge, Mass., appointed John Flaherty vice president, medical affairs.
U.S. Genomics, of Woburn, Mass., appointed David Hoey vice president, business development.
Vasogen Inc., of Toronto, appointed Stanley Appel to its scientific advisory board.
VaxGen Inc., of Brisbane, Calif., added David Beier to its board.
Visible Genetics Inc., of Toronto, added David Galloway to its board.
Xenon Genetics Inc., of Vancouver, British Columbia, appointed Simon Pimstone chief operating officer and added Celia Courchene as vice president, business development.